Per Pfeiffer

发表

Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer.

P. Pfeiffer, K. Bertelsen, K. Bertelsen, 1990, Gynecologic oncology.

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.

P. Pfeiffer, B. Jensen, J. Bjerregaard, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.

H. Sorbye, L. Balteskard, P. Pfeiffer, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.

P. Pfeiffer, A. Jakobsen, K. Aabo, 2006, European journal of cancer.

Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer.

H. Sorbye, M. Cvancarova, B. Glimelius, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

UFT (tegafur-uracil) in rectal cancer.

J. Feliu, P. Pfeiffer, E. Casado, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum Katrine R. SchoennemannJon K. BjerregaardTine P. HansenKarin De Stricker • Morten F. GjerstorffHelle A. JensenLene W. VestermarkPer Pfeiffer

J. Bjerregaard, L. Vestermark, H. A. Jensen, 2011 .

Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature.

O. Hansen, H. Aagaard, P. Pfeiffer, 1996, Acta oncologica.

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis.

V. Moiseenko, R. Glynne-Jones, N. Amellal, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

T. Hansen, P. Pfeiffer, L. Tarpgaard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Comment on ESMO Magnitude of Clinical Benefit Scale.

H. Joensuu, P. Pfeiffer, T. Muhonen, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.

P. Pfeiffer, D. Nielsen, B. Jensen, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study.

E. Van Cutsem, C. Punt, V. Moiseenko, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.